Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
Scope of the Report:This report studies the Solid Tumors Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Solid Tumors Drugs market by product type and applications/end industries.
During 2017, the biologics segment dominated the market and accounted for close to 55% of the market share in terms of revenue. This segment consists of medicinal products extracted from biological sources such as human, animal, microorganisms, or they are manufactured using the latest, cutting-edge biotechnological processes. Biologics include products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.
In terms of geography, the Americas dominated the global solid tumors drugs market. The growth of this market in the Americas is attributed to the increasing uptake of existing biologics drugs and the launch of new biologics. However, the revenue from these drugs will decrease during the forecast period because of the loss of patent exclusivity of drugs, leading to the entry of generics. This decline is expected to be partially offset by favorable reimbursement plans by the government, such as the provision of Medicare and Medicaid. The US is the largest revenue contributor in this region.
The global Solid Tumors Drugs market is valued at xx million USD in 2020 and is expected to reach xx million USD by the end of 2026, growing at a CAGR of xx% between 2020 and 2026.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Solid Tumors Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2020 and will be xx million USD in 2026, with a CAGR of xx%.
Market Segment by Companies, this report covers Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
Eli Lilly
GSK
Merck
Sanofi
AbbVie
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim
Boston Biomedical
Daiichi Sankyo
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers Small Molecules
Biologics
Market Segment by Applications, can be divided into Hospitals
Clinics
Academic and Research Institutes
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
